Stage III non-small cell lung cancer(NSCLC) patient who without surgical treatment
Patients scheduled for curative concurrent chemoradiotherapy
* chemotherapy : paclitaxel and carboplatin
* radiation therapy : IMRT, total 60\~70Gy
Eastern Cooperative Oncology Group(ECOG) performance status of 0 to 2 at the screening visit
Subject whose remaining life expectancy is more than 6 months according to the judgment of investigator
Volunteer, be willing and able to provide written informed consent for the trial
You may not be if
Subjects with pleural effusion
Subjects with a weight loss of 10% or more within the last 6 months from the screening visit
Subjects with a history of thoracic or neck radiotherapy or chemotherapy prior to screening visit
Subjects with distant metastases
Subjects with liver/renal dysfunction according to the following criteria on the screening test
* Total Bilirubin \>1.5 mg/dL
* ALT or AST level is 2.0 times higher than the upper limit of normal (based on the institution)
* Serum Creatinine \>1.5 mg/dL
Subjects with serious cardiovascular disease within 3 months prior to the screening visit (ex. arrhythmia, congestive heart failure, infarction, unstable angina etc)
Subjects with serious systemic infection (≥ Grade 3, evaluated by CTCAE v5.0)
Patients with chronic or interstitial lung disease (excluding patients with chronic obstructive pulmonary disease (COPD)), patients with chronic bronchitis, patients with pneumonia
Subjects with thyroid dysfunction as present illness at the screening visit
Subjects who administered systemic steroids within 4 weeks prior to the date of randomization (except for cases when administered to prevent hypersensitivity reaction of paclitaxel)
Subjects who are hypersensitive to investigational products and standard anticancer treatments
Subjects who participate in other clinical trials within 30 days prior to the screening visit and administer investigational drugs or apply clinical trial medical devices
Women of childbearing age or men who do not agree to use a medically accepted method of contraception during the clinical trial
Pregnant or breast-feeding
Subjects who have clinical significance that is considered inappropriate for this clinical trial as judged by the investigator
Clareo Health | Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients
